Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009876014 | Endometrium | EEC | response to interleukin-7 | 6/2168 | 15/18723 | 4.74e-03 | 3.00e-02 | 6 |
GO:009876114 | Endometrium | EEC | cellular response to interleukin-7 | 6/2168 | 15/18723 | 4.74e-03 | 3.00e-02 | 6 |
GO:004659814 | Endometrium | EEC | positive regulation of viral entry into host cell | 5/2168 | 11/18723 | 5.24e-03 | 3.26e-02 | 5 |
GO:007529414 | Endometrium | EEC | positive regulation by symbiont of entry into host | 5/2168 | 11/18723 | 5.24e-03 | 3.26e-02 | 5 |
GO:003629414 | Endometrium | EEC | cellular response to decreased oxygen levels | 30/2168 | 161/18723 | 5.66e-03 | 3.40e-02 | 30 |
GO:00714567 | Endometrium | EEC | cellular response to hypoxia | 28/2168 | 151/18723 | 7.84e-03 | 4.36e-02 | 28 |
GO:190288215 | Endometrium | EEC | regulation of response to oxidative stress | 20/2168 | 98/18723 | 7.99e-03 | 4.44e-02 | 20 |
GO:000645720 | Esophagus | HGIN | protein folding | 75/2587 | 212/18723 | 1.61e-15 | 3.86e-13 | 75 |
GO:001603227 | Esophagus | HGIN | viral process | 118/2587 | 415/18723 | 3.01e-15 | 6.22e-13 | 118 |
GO:009719327 | Esophagus | HGIN | intrinsic apoptotic signaling pathway | 90/2587 | 288/18723 | 1.50e-14 | 2.80e-12 | 90 |
GO:003497625 | Esophagus | HGIN | response to endoplasmic reticulum stress | 81/2587 | 256/18723 | 1.47e-13 | 2.32e-11 | 81 |
GO:001905827 | Esophagus | HGIN | viral life cycle | 93/2587 | 317/18723 | 3.66e-13 | 5.63e-11 | 93 |
GO:200124227 | Esophagus | HGIN | regulation of intrinsic apoptotic signaling pathway | 58/2587 | 164/18723 | 2.57e-12 | 3.58e-10 | 58 |
GO:200123327 | Esophagus | HGIN | regulation of apoptotic signaling pathway | 97/2587 | 356/18723 | 1.36e-11 | 1.57e-09 | 97 |
GO:000697927 | Esophagus | HGIN | response to oxidative stress | 107/2587 | 446/18723 | 3.91e-09 | 2.76e-07 | 107 |
GO:005079225 | Esophagus | HGIN | regulation of viral process | 50/2587 | 164/18723 | 2.53e-08 | 1.49e-06 | 50 |
GO:190390025 | Esophagus | HGIN | regulation of viral life cycle | 45/2587 | 148/18723 | 1.36e-07 | 6.78e-06 | 45 |
GO:004852419 | Esophagus | HGIN | positive regulation of viral process | 25/2587 | 65/18723 | 6.88e-07 | 2.95e-05 | 25 |
GO:004440326 | Esophagus | HGIN | biological process involved in symbiotic interaction | 71/2587 | 290/18723 | 7.09e-07 | 3.00e-05 | 71 |
GO:006219727 | Esophagus | HGIN | cellular response to chemical stress | 76/2587 | 337/18723 | 8.00e-06 | 2.41e-04 | 76 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0414124 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
hsa0414134 | Breast | IDC | Protein processing in endoplasmic reticulum | 36/867 | 174/8465 | 2.73e-05 | 2.86e-04 | 2.14e-04 | 36 |
hsa0414143 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
hsa0414153 | Breast | DCIS | Protein processing in endoplasmic reticulum | 36/846 | 174/8465 | 1.60e-05 | 1.91e-04 | 1.41e-04 | 36 |
hsa0414120 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa04141110 | Cervix | CC | Protein processing in endoplasmic reticulum | 55/1267 | 174/8465 | 1.74e-08 | 2.68e-07 | 1.58e-07 | 55 |
hsa04141 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
hsa041411 | Colorectum | AD | Protein processing in endoplasmic reticulum | 80/2092 | 174/8465 | 5.96e-10 | 1.25e-08 | 7.96e-09 | 80 |
hsa041414 | Colorectum | MSS | Protein processing in endoplasmic reticulum | 75/1875 | 174/8465 | 3.78e-10 | 8.44e-09 | 5.17e-09 | 75 |
hsa041415 | Colorectum | MSS | Protein processing in endoplasmic reticulum | 75/1875 | 174/8465 | 3.78e-10 | 8.44e-09 | 5.17e-09 | 75 |
hsa041416 | Colorectum | MSI-H | Protein processing in endoplasmic reticulum | 46/797 | 174/8465 | 4.53e-11 | 9.78e-10 | 8.19e-10 | 46 |
hsa041417 | Colorectum | MSI-H | Protein processing in endoplasmic reticulum | 46/797 | 174/8465 | 4.53e-11 | 9.78e-10 | 8.19e-10 | 46 |
hsa041418 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
hsa041419 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
hsa0414126 | Endometrium | AEH | Protein processing in endoplasmic reticulum | 62/1197 | 174/8465 | 5.97e-13 | 1.39e-11 | 1.01e-11 | 62 |
hsa04141111 | Endometrium | AEH | Protein processing in endoplasmic reticulum | 62/1197 | 174/8465 | 5.97e-13 | 1.39e-11 | 1.01e-11 | 62 |
hsa0414127 | Endometrium | EEC | Protein processing in endoplasmic reticulum | 64/1237 | 174/8465 | 2.17e-13 | 5.09e-12 | 3.80e-12 | 64 |
hsa0414136 | Endometrium | EEC | Protein processing in endoplasmic reticulum | 64/1237 | 174/8465 | 2.17e-13 | 5.09e-12 | 3.80e-12 | 64 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
P4HB | SNV | Missense_Mutation | | c.1439N>T | p.Asp480Val | p.D480V | P07237 | protein_coding | tolerated(0.3) | possibly_damaging(0.454) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
P4HB | SNV | Missense_Mutation | novel | c.431C>A | p.Ala144Glu | p.A144E | P07237 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
P4HB | SNV | Missense_Mutation | novel | c.431N>A | p.Ala144Glu | p.A144E | P07237 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
P4HB | SNV | Missense_Mutation | rs138621837 | c.430N>A | p.Ala144Thr | p.A144T | P07237 | protein_coding | tolerated(0.51) | benign(0.003) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
P4HB | SNV | Missense_Mutation | novel | c.1089N>G | p.Asp363Glu | p.D363E | P07237 | protein_coding | deleterious(0.02) | benign(0.036) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
P4HB | SNV | Missense_Mutation | | c.1163N>G | p.Val388Gly | p.V388G | P07237 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
P4HB | insertion | Frame_Shift_Ins | novel | c.1453_1454insCCTGGAATCCCAGTGCTGGGGC | p.Glu485AlafsTer23 | p.E485Afs*23 | P07237 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
P4HB | deletion | Frame_Shift_Del | rs773547908 | c.1160delN | p.Asn387ThrfsTer118 | p.N387Tfs*118 | P07237 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
P4HB | deletion | Frame_Shift_Del | rs773547908 | c.1160delN | p.Asn387ThrfsTer118 | p.N387Tfs*118 | P07237 | protein_coding | | | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
P4HB | SNV | Missense_Mutation | novel | c.649N>C | p.Glu217Gln | p.E217Q | P07237 | protein_coding | deleterious(0.03) | possibly_damaging(0.556) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | RALOXIFENE HYDROCHLORIDE | RALOXIFENE HYDROCHLORIDE | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | ASTRAGALIN | ASTRAGALIN | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | SYROSINGOPINE | SYROSINGOPINE | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | LIQUIRITIN | LIQUIRITIN | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | QUERCITRIN | QUERCITRIN | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2105662 | LOMITAPIDE MESYLATE | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | NSC-19803 | CHEMBL522983 | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | DIHYDRODAPHNODORIN B | DIHYDRODAPHNODORIN B | |
5034 | P4HB | THIOREDOXIN, DRUGGABLE GENOME, ENZYME, EXTERNAL SIDE OF PLASMA MEMBRANE | | GNF-PF-2976 | CHEMBL579956 | |